From Dormant to Dominant: The ETF Powering Biotech’s New Bull Run

Innovation never sleeps—and lately, one sector is lighting up again with the kind of surge that demands attention. Biotech, long dismissed by skeptics, is awakening on the back of falling interest rates, revived deal-making, and urgent pressure on Big Pharma to refill its drug pipelines. Mergers and acquisitions are creeping back into view as blockbuster patents begin to expire, making smaller biotech names even more tempting targets. The case for rallying risk assets is strengthening—and this particular ETF has begun to reflect that shift. The uptrend is unmistakable, momentum is building, and the charts suggest there’s room to run further.

And that momentum isn’t just a passing wave — it’s fundamental. The ETF I’m watching closely here is the SPDR S&P Biotech ETF (XBI), and the setup on this one is powerful. XBI has now broken above every major trendline on the chart — a rare show of strength that confirms buyers are firmly in control. What’s even more compelling is that its 50-day EMA just crossed above the 100-day EMA, one of my favorite long-term trend confirmation signals. That tells us the underlying demand isn’t just speculative — it’s rooted in a broad, sustained rotation back into high-growth biotech names. With rates moving lower, M&A heating up, and risk appetite returning, XBI’s breakout looks like the start of something much bigger. Traders looking for leadership in this next leg higher would be wise to keep this one front and center on their radar.

See how Chuck looks to earn an average of $126 in cash payouts per week. His focus on leveraging time is now yours to learn.

When I see a chart as strong as XBI’s, I want to take full advantage of that momentum — and for me, that means a directional call option purchase. XBI’s trend structure is incredibly encouraging right now, with price holding firm above all key averages and showing the kind of technical resilience that often precedes a powerful continuation move. If this breakout continues to build, I want a trade that’s positioned to capture maximum upside. That’s why I’m looking at a slightly in-the-money call — at current prices, it offers a potential profit of 100.5% if XBI climbs just 10% by expiration. That kind of asymmetric reward profile is exactly what I look for in a high-confidence bullish setup.

If you want to learn how to identify trades like this one — and get multiple actionable setups every week — you need to be part of our flagship program, The Optioneering Newsletter. This is where we break down the exact technical analysis methods behind our best trade ideas and share our top opportunities in real time. And right now, you can get in for a full month trial for just $1 — four weeks of live trade alerts, analysis, and strategy for less than what most people spend to download a single app on their phone. Opportunities like this don’t wait… and neither should you. 👉 Start your $1 trial of The Optioneering Newsletter today — and see the difference that precision trading can make.

Wishing You the Best in Investing Success,